Indian Journal of Nephrology · 2013 · 18 citations · 17 references
MedicineNephrologyPharmacologyMetastasisRenal PathologyRenal PharmacotherapyKidney CancerMetastatic Disease TreatmentNephrotic SyndromeRenal Cell CarcinomaRenal DiseaseRenal NeoplasmsMetastatic Renal Cell Carcinoma TherapyNephrotic Syndrome TreatmentPodocyte Foot Process EffacementRenal Biopsy DiagnosisRenal Biopsy FindingsTyrosine Kinase Inhibitor TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor Inhibition
Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor and platelet derived growth factor receptor. It is used for the treatment of metastatic renal cell carcinoma (RCC). Use of sunitinib has been associated with renal dysfunction and nephrotic syndrome. However, simultaneous occurrence of nephrotic syndrome and renal dysfunction in a patient treated with sunitinib is rare. We report a case of metastatic RCC treated with sunitinib for 22 months who presented with nephrotic syndrome and renal dysfunction. Renal biopsy was diagnostic of thrombotic microangiopathy with diffuse effacement of podocytic foot process.
17
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +14
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Oncology, Pharmacology +13